Next 10 |
home / stock / onppf / onppf news
Oncopeptides ( OTC:ONPPF ) said a majority of a panel of the U.S. Food and Drug Administration (FDA) considered that data from a phase 3 trial called OCEAN did not confirm a favorable benefit-risk profile of the company's blood cancer therapy Pepaxto. Pepaxto&...
The following slide deck was published by Oncopeptides AB (publ) in conjunction with their 2022 Q2 earnings call. For further details see: Oncopeptides AB (publ) 2022 Q2 - Results - Earnings Call Presentation
Oncopeptides AB press release ( OTC:ONPPF ): Q2 GAAP EPS of -SEK0.79. Revenue of SEK8.8M (-86.7% Y/Y). For further details see: Oncopeptides AB GAAP EPS of -SEK0.79, revenue of SEK8.8M
FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides' Pepaxto PR Newswire STOCKHOLM , July 20, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on resear...
A committee of the European Medicines Agency (EMA) recommended the full marketing authorization approval of Oncopeptides (OTCPK:ONPPF) its blood cancer therapy Pepaxti (melphalan flufenamide). Pepaxti, was sold as Pepaxto in the U.S. and was pulled from the market by the Stockh...
Oncopeptides AB press release (OTCPK:ONPPF): Q1 Non-GAAP EPS of -SEK1.13. Cash balances at the end of the period amounted to SEK 194.3M For further details see: Oncopeptides AB Non-GAAP EPS of -SEK1.13
Oncopeptides AB press release (OTCPK:ONPPF): GAAP EPS of -SEK5.23. Cash balances at the end of the period amounted to SEK362.2 M For further details see: Oncopeptides AB GAAP EPS of -SEK5.23
Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US - no intent to market in the US at this time PR Newswire STOCKHOLM , Jan. 21, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and deve...
Oncopeptides AB (OTCPK:ONPPF): Q3 GAAP EPS of -SEK 10.33. Revenue of SEK 54.28M Press Release Cash and cash equivalents amounted to SEK 671.3M as on September 30. For further details see: Oncopeptides AB reports Q3 results
Many wonder about an upcoming bear market. For me, this is a simple answer - the bear is already here. At least in Sweden and Scandinavia and for some companies. For months now since early August, the indexes here have been punished, and we're down more than 10%, correction. However, ...
News, Short Squeeze, Breakout and More Instantly...
Oncopeptides Company Name:
ONPPF Stock Symbol:
OTCMKTS Market:
FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides' Pepaxto PR Newswire STOCKHOLM , July 20, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on resear...
Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US - no intent to market in the US at this time PR Newswire STOCKHOLM , Jan. 21, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and deve...
Oncopeptides presents phase 3 OCEAN study results at the IMW meeting PR Newswire STOCKHOLM , Sept. 11, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat he...